Dupilumab De-escalation in Pediatric Atopic Dermatitis
Status:
Recruiting
Trial end date:
2027-04-30
Target enrollment:
Participant gender:
Summary
This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of
dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have
achieved sustained atopic dermatitis (AD) control on dupilumab.